PhD Scientific Days 2024

Poster Session R - Pharmaceutical Sciences and Health Technologies 2.

Advancing Lyme Disease Treatment through the Repositioned Disulfiram Drug Delivery System

Előadó neve

Dr. Benkő, Beáta-Mária

Neptun code

PRCN09

Előadó munkahelye

University Pharmacy Department of Pharmacy Administration, Semmelweis University

Előadó telefonszáma

06309527963

Előadó e-mail címe

benko.beata@phd.semmelweis.hu

Az előadás címe

Advancing Lyme Disease Treatment through the Repositioned Disulfiram Drug Delivery System

Szerző(k) neve és munkahelye

Beáta Mária Benkó¹, Gergő Tóth², Bálint Szabó³, Szabina Kádár⁴, Edina Szabó⁴, Zoltán-István Szabó⁵, Lajos Szente⁶, Péter Tonka Nagy³, Romána Zelkó¹, István Sebe¹

1: University Pharmacy Department of Pharmacy Administration, Semmelweis University
2: Department of Pharmaceutical Chemistry, Semmelweis University
3: Egis Pharmaceuticals Plc., R&D Directorate
4: Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics
5: Faculty of Pharmacy Department of Drugs Industry and Pharmaceutical Management, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures
6: CycloLab Cyclodextrin Research & Development Laboratory Ltd

Bemutatás módja

Poszter

Szekció

Poster Session R - Pharmaceutical Sciences and Health Technologies 2.

Language of the presentation

English

Preferred session

Pharmaceutical Sciences and Health Technologies

Összefoglaló szövege

Introduction: Lyme disease is the most common tick-borne disease in the U.S. and Europe. Disulfiram (DIS) worldwide is used in chronic alcoholism treatment as oral or, in the near past, implantable tablets, topically against head lice, flat lice, and scabies. It recently is gaining ground for Lyme disease treatment. However, due to poor oral bioavailability, the drug fails to achieve the translational goal in the new potential indication scope.
Aim: Given the significant clinical interest, the promising results from preclinical trials, and the off-label use of DIS, our team undertook a comprehensive systematic literature review. This review was crucial in evaluating the drug's current status in Lyme disease, emphasizing its clinical relevance and identifying its translational issues. Using pharmaceutical technology tools, a proposal composition and a non-invasively administrable pharmaceutical form was developed.
Methods: Cyclodextrin (CD) inclusion complexes were studied for solubility and stability enhancement. Solubility study and solid-state characterization of the inclusion complexes were assessed to determine the suitable combination. The developed formulation relates to a novel preparation for rectal administration comprising a mixture of DIS with random methylated-β-CD and hydroxypropyl-β-CD.
Results: The molecular encapsulation of the drug with CDs leads to improved solubility and, consequently, a more favorable bioavailability. The advantage of DIS suppository over peroral administration is that the rectal route is less susceptible to the first-pass effect. This, in turn, allows for a reduction in the required dose and a decrease in the risk of adverse effects, making it a potentially safer and more effective treatment option.
Conclusion: Combining the pharmaceutically relevant CDs and the already approved chemical entity is advantageous for drug repositioning strategies, optimizing the innovation triangle — basic research, applied research, and drug development. The traditional non-invasive rectal dosage form of DIS presents the advantage of production in laboratory pharmacies, fasting the availability of the drug for patients with Lyme disease.
Funding: Supported by the ÚNKP-23-3-II-SE-95 New National Excellence Program of the Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund

University

Semmelweis University

Other university, not listed above

-

Supervisor

Dr. Sebe István

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7451

Start

16:35

End

16:38